Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasburicase for Hyperuricemia in Relapsing Aggressive NHL (GRAAL2)
NCT00664144Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Jul 2002
- Primary completion
- Jan 2005
- Modality
- Replacement Enzymes
- Countries
- 4
01
Overview
A Phase 2 trial of rasburicase in hyperuricemia, tumor lysis syndrome (TLS), sponsored by Sanofi. Started Jul 2002; status: terminated.
02
Drugs
rasburicase
03
Conditions
hyperuricemiatumor lysis syndrome (TLS)
Beyond the preview
Go deeper on NCT00664144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00664144.